135
Participants
Start Date
March 18, 2019
Primary Completion Date
December 23, 2019
Study Completion Date
January 30, 2020
Valbenazine
vesicular monoamine transporter 2 (VMAT2) inhibitor
Placebo oral capsule
non-active dosage form
Neurocrine Clinical Site, New York
Neurocrine Clinical Site, Scranton
Neurocrine Clinical Site, Conshohocken
Neurocrine Clinical Site, Petersburg
Neurocrine Clinical Site, Orlando
Neurocrine Clinical Site, Hialeah
Neurocrine Clinical Site, Hialeah
Neurocrine Clinical Site, Hialeah
Neurocrine Clinical Site, North Miami
Neurocrine Clinical Site, Miami
Neurocrine Clinical Site, Franklin
Neurocrine Clinical Site, Houston
Neurocrine Clinical Site, Beachwood
Neurocrine Clinical Site, Mason
Neurocrine Clinical Site, South Bend
Neurocrine Clinical Site, Bloomfield Hills
Neurocrine Clinical Site, East Lansing
Neurocrine Clinical Site, Grand Rapids
Neurocrine Clinical Site, St Louis
Neurocrine Clinical Site, Kansas City
Neurocrine Clinical Site, Lincoln
Neurocrine Clinical Site, Little Rock
Neurocrine Clinical Site, Oklahoma City
Neurocrine Clinical Site, Irving
Neurocrine Clinical Site, DeSoto
Neurocrine Clinical Site, Houston
Neurocrine Clinical Site, Richmond
Neurocrine Clinical Site, Pueblo
Neurocrine Clinical Site, Las Vegas
Neurocrine Clinical Site, Torrance
Neurocrine Clinical Site, La Habra
Neurocrine Clinical Site, Norwalk
Neurocrine Clinical Site, Glendale
Neurocrine Clinical Site, Lemon Grove
Neurocrine Clinical Site, Escondido
Neurocrine Clinical Site, San Diego
Neurocrine Clinical Site, San Bernardino
Neurocrine Clinical Site, Costa Mesa
Neurocrine Clinical Site, Fountain Valley
Neurocrine Clinical Site, Anaheim
Neurocrine Clinical Site, Anaheim
Neurocrine Clinical Site, Spokane
Neurocrine Clinical Site, San Juan
Lead Sponsor
Neurocrine Biosciences
INDUSTRY